Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensoril for persistent symptoms in schizophrenia
NCT03437668Phase 3Terminated
- Start
- Dec 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of withania somnifera in schizophrenia, schizoaffective disorder. Started Dec 2018; status: terminated.
02
Drugs
withania somnifera
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03437668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437668.